Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study

Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study

Abstract Research investigating incident malignancy risk in erythropoiesis‐stimulating agent (ESA) users with chronic kidney disease (CKD) is lacking. We aimed to compare the incident cancer risk between ESA and non‐ESA users with CKD or end‐stage renal disease (ESRD). In this retrospective cohort s...

Full description

Bibliographic Details
Main Authors: Yu‐Shan Huang, Ming‐Feng Li, Mei‐Chen Lin, Shih‐Hsiang Ou, Jen‐Hung Wang, Chien‐Wei Huang, Kang‐Ju Chou, Hua‐Chang Fang, Po‐Tsang Lee, Chih‐Yang Hsu, Jin‐Shuen Chen, Hsin‐Yu Chen
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13353

Internet

https://doi.org/10.1111/cts.13353

Similar Items